newsfilter
← Latest News
PR Newswire·

CTI BioPharma Reports First Quarter 2022 Financial Results

– Strong U.S. commercial launch of VONJO™ (pacritinib) underway following accelerated FDA approval for the treatment of adult patients with Myelofibrosis and Thrombocytopenia – – VONJO (pacritinib) net product revenue of $2.3 million in less t